Browsing Tag
Novartis
83 posts
Senhwa Biosciences expands CX-5461 into photodynamic therapy as AACR 2026 spotlight raises strategic optionality
Senhwa Biosciences expands CX-5461 into photodynamic therapy. Discover how this dual-mechanism strategy could reshape oncology innovation today.
How the Faculty deal strengthens Accenture’s position in the global AI consulting market (NYSE: ACN)
Accenture completes its acquisition of AI firm Faculty and appoints Marc Warner as CTO. Discover how the deal strengthens Accenture’s enterprise AI consulting strategy.
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
Avidity Biosciences (Nasdaq: RNA) opens access to del-zota in DMD44 as BLA filing nears
Avidity Biosciences launches U.S. access program for del-zota in DMD exon 44 patients. See how this ties into FDA submission plans and the Novartis acquisition.
Can psoriatic disease remission be redefined? Inside the shift toward zero activity in targeted domains
Discover how zero disease activity in one or more domains is reshaping psoriatic care, pharma strategy, and future treatment benchmarks.
Inhibrx Biosciences’ Ozekibart sets new benchmark in rare bone cancer treatment and advances toward 2026 BLA filing
Find out how Inhibrx Biosciences’ Ozekibart delivered breakthrough results in chondrosarcoma and is advancing toward a 2026 BLA filing—read more now!
How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy
Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025.
Can longevity biotech finally go mainstream — or is BioAge’s $250m shelf another warning sign of investor fatigue?
BioAge Labs (NASDAQ: BIOA) files a $250M shelf to fund aging-drug programs. Can disciplined financing revive investor faith in longevity biotech?
From IPO to $250M shelf: Can BioAge Labs keep investor faith in the race for anti-aging drugs?
BioAge Labs (NASDAQ: BIOA) files $250M mixed securities shelf to fuel its aging drug pipeline. See what it means for investors today.